U.S. FDA Notes Nine Issues at Cipla’s Indore-based Manufacturing Unit

FDA investigators noted that the quality control system of the unit lacked authority to review production records to assure that no errors have occurred.

Indian drug maker Cipla has been served nine observations by the U.S. Food and Drug Administration (FDA) for its Indore-based manufacturing unit as part of an inspection that was conducted during July and August this year. The observations is a summary note of issues noticed by the FDA officials and needs corrections.

Cipla remains amongst the few large domestic companies that has so far not faced tough regulatory actions from the US FDA.

Cipla Pharma Appoints Dr Reddy�s Former Us Generics Head As Global CFO
Umang Vohra as Cipla’s Global Chief Financial and Strategy Officer would bring deep insights about the global generics industry and understanding of value creation.

While the company declined to share details of the US Food and Drug Administration (US FDA) observations, brokers said as many as nine issues have been raised by the regulator under ‘Form 483’ regarding manufacturing practices in the plant.

A company is required to respond to the US FDA in writing with its corrective action plan and then implement that corrective action plan expeditiously.

More specifically, they said in the note that an out-of-specification for levalbuterol inhalation solution resulted in a voluntary recall of one batch from the US market in May 215. "However the investigation did not extend into other strengths of the product to determine the product's quality, safety and stability," the observation which is part of the Form 483 said.

Cipla Urges Government to Support Capital Investment, Encourage Research & Development
The government should bring in attractive market conditions by supporting capital investment, encourage R&D and create a favourable tax environment, said Cipla chairman.

In another observation, a failure related to a leakage was documented 35 times but no investigation was initiated to identify problems that may potentially affect the product safety and quality.

The observation further stated that a failure related to a leakage was documented 35 times and no investigations were taken place in the matter, which might have affected the product safety and quality.

New Low-Cost Drug Manufactured by Cipla Launched in Uganda for HIV Treatment
The single-dose Trioday treatment, which costs $13 per month, replaces the cumbersome 12-drug cocktails which was the only option for people with HIV.

Cipla's Indore unit has also been faulted for facility and equipment systems. The officials observed that aseptic processing areas were deficient regarding the system for monitoring environmental conditions.
The US FDA staff stated the sterile filling lines were opened quite often in order to complete manual interventions during product filling. .

Source-Medindia

FDA Approves Cipla�s Drug Delivery System for Infants and Children Suffering from HIV
Oral pellets are preferred antiretroviral in pediatric patents and this drug delivery system is a breakthrough in pediatric-specific treatment for infants.